Safety and Tolerability of a 13-Valent Pneumococcal Conjugated Vaccine Distributed in the Public Immunization Program of the Municipality of Campos dos Goytacazes, Rio de Janeiro, Brazil
Charbell Miguel Kury, Annelise Maria Wilken, Raquel Mesquita Henriques, Renata de Salles, Wilza Abreu de Brito, Marcus Miguel Kury, Rafael Pessanha de Sá, Felipe Pessanha de Sá
Medicine School of the Munici- pality of Campos dos Goytacazes, State of Rio de Janeiro, Brazil..
Secretariat of Health, Municipality of Campos dos Goytacazes, State of Rio de Janeiro, Brazil.
Secretariat of Health, Municipality of Campos dos Goytacazes, State of Rio de Janeiro, Brazil; Medicine School of the Munici- pality of Campos dos Goytacazes, State of Rio de Janeiro, Brazil..
Secretariat of Health, Municipality of Campos dos Goytacazes, State of Rio de Janeiro, Brazil; Medicine School of the Municipality of Campos dos Goytacazes, State of Rio de Janeiro, Brazil..
DOI: 10.4236/wjv.2012.24026   PDF    HTML     4,566 Downloads   6,843 Views  

Abstract

From september to december, 2010, we have assessed the frequency and occurrence of adverse events to Pneumo-coccal conjugated 13-valent vaccine (PCV-13) in the Public vaccination program of the municipality of Campos dos Goytacazes, State of Rio de Janeiro, the unique city in Brazil that has introduced this vaccine in it’s immunization schedule. This study analyzed 1001 toddlers who have received PCV-13 at 3, 5 and 7 months and a booster dose at 12 months. We observed a total of 514 local and systemic events in 303 subjects (30.2% of 1001 infants). The most reported systemic events were irritability (18.8%) and fever < 38.5°C (17.1%), followed by fever > or = 38.5°C (8.8%), loss of appetite (8.4%). Erythema (11.2%) and local pain (9.4%) were the most reported local events. Other events reported were diarrhea (6.2%), increased sleep (5.1%), edema and induration (4.8%), decreased sleep (4.3%), vomiting (1.4%), eruption (1.2%) urticaria (0.8%), prurience (0.8%), lymphadenopathy (0.2%) and hypersensitivity reaction (0.2%). There wasn’t any reported case of convulsion or Hospital admission. When stratified by each dose, irritability (systemic) and erythema (local) were the most common events reported at the first and fourth dose, although fever < 38.5°C (systemic) and pain (local) were the most common at second and third doses. Results were close to those encountered in product monograph. In our study, PCV-13 was secure in pneumococcal disease prevention and well tolerated.

Share and Cite:

C. Kury, A. Wilken, R. Henriques, R. Salles, W. Brito, M. Kury, R. Sá and F. Sá, "Safety and Tolerability of a 13-Valent Pneumococcal Conjugated Vaccine Distributed in the Public Immunization Program of the Municipality of Campos dos Goytacazes, Rio de Janeiro, Brazil," World Journal of Vaccines, Vol. 2 No. 4, 2012, pp. 189-193. doi: 10.4236/wjv.2012.24026.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] World Health Organization, “Pneumococcal Conjugate Vaccine for Childhood Immunization,” 2007. http://www.who.int/wer/2007/wer8212
[2] L. Ferro, et al., “Pneumococcal Conjugate Vaccine Impact against Invasive Disease Caused by Streptococcus pneumoniae,” Brazilian Journal of Pediatrics, Vol. 82, No. 3, 2006, pp. S67-S74.
[3] G. Vespa, D. O. Constela, C. Pepe, M. A. Safadi, E. Berezin, et al., “Estimating the Cost Effectiveness of Pneumococcal Conjugate Vaccination in Brazil,” Pan American Journal of Public Health, Vol. 26, No. 6, 2009, pp. 518-28. doi:10.1590/S1020-49892009001200007
[4] D. Constela, “Evaluating the Costs of Pneumococcal Disease in Selected Latin American Coutries,” Revista Panamericana de Salud Pública, Vol. 22, No. 4, 2007, pp. 268-278.
[5] Center of Disease Control and Prevention, “Invasive Pneumococcal Disease in Young Children before Licensure of 13-Valent Pneumococcal Conjugate Vaccine— United States, 2007,” Morbity and Mortality Weekly Report, Vol. 59, No. 9, 2010, pp. 253-257.
[6] S. I. Pelton, H. Huot, J. A. Finkelstein, et al., “Emergence of 19A as Virulent and Multidrug Resistant Pneumococcus in Massachusets Following Universal Immunization of Infants with Pneumococcal Conjugate Vaccine,” The Pediatric Infectious Disease Journal, Vol. 26, No. 6, 2007, pp. 468-472. doi:10.1097/INF.0b013e31803df9ca
[7] Centers for Disease Control and Prevention, “Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae—Massachusetts. 2001-2006,” Morbity and Mortality Weekly Report, Vol. 56, No. 41, 2007, pp. 1077-1080.
[8] T. Pilishvili, C. Lexau, M. M. Farley, et al., “Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine,” The Journal of Infectious Diseases, Vol. 201, No. 1, 2010, pp. 32-41. doi:10.1086/648593
[9] E. C. Dinleyici and Z. A. Yargic, “Current Knowledge Regarding the Investigational 13-Valent Pneumococcal conjugate Vaccine,” Expert Review of Vaccines, Vol. 8, No. 8, 2009, pp. 977-986. doi:10.1586/erv.09.68
[10] Food and Drug Administration (FDA), “Vaccines: Approved Products. Prevnar 13 (Pneumococcal 13-Valent Conjugate Vaccine),” 2010. http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm201667.htm
[11] Pfizer? and Wyeth?. “Pneumococcal 13-Valent Conjugate Vaccine Monography Product (“Prevenar 13”),” Brazilian Ministery of Healthy, 2010.
[12] A. G. Dean and K. M. Sullivan, “OpenEpi Collection of Epidemiologic Calculators,” Version 2.3, 2009. http://www.openepi.com/OE2.3/Menu/OpenEpiMenu.htm
[13] K. A. Bryant, S. L. Block, S. A. Baker, et al., “Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine,” Pediatrics, Vol. 125, No. 5, 2010, p. 866-875.
[14] S. T. Duggan, “Pneumococcal Polysaccharide conjugate vaccine (13-Valent, Adsorbed) [PREVENAR 13?],” Drugs, Vol. 70, No. 15, 2010, pp. 1973-1986. doi:10.2165/11205110-000000000-00000
[15] M. D. Snape, C. L. Klinger, E.D. Daniels, et al., “Immunogenicity and Reactogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Administered at 2, 4 and 12 Months of Age,” The Pediatric Infectious Disease Journal, Vol. 29, No. 12, 2010, pp. e80-e90. doi:10.1097/INF.0b013e3181faa6be
[16] O. G. Vanderkooi, D. W. Scheifele, D. Girgenti, et al., “Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given with Routine Pediatric Vaccinations in Canada,” The Pediatric Infectious Disease Journal, Vol. 31, No. 1, 2012, pp. 72-77. doi:10.1097/INF.0b013e318233049d

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.